Patent ID: 9745630
Date: 2017-08-29
CPC Classifications: A61N,C12Q

Claim:
1. A method for diagnosing prostate cancer, comprising: (a) determining an expression profile of hsa-miR-144* (SEQ ID NO:714) and hsa-miR-148a (SEQ ID NO:701) in blood cells obtained from a blood sample from a subject suspected to be affected by prostate cancer, wherein said blood cells consist of erythrocytes, leukocytes and thrombocytes and are obtained by removing the acellular fraction from the blood sample, and wherein determining said expression profile comprises nucleic acid amplification performed using real-time polymerase chain reaction (RT-PCR), (b) comparing said expression profile to a reference expression profile of healthy subjects, (c) diagnosing the presence of prostate cancer in the subject suspected to be affected by prostate cancer when down-regulation of each of hsa-miR-144* and hsa-miR-148a is detected in comparison to the reference expression profile, and (d) subjecting the subject diagnosed to be affected by prostate cancer to therapy for prostate cancer selected from the group consisting of surgery, radiation therapy, hormonal therapy, chemotherapy, cryosurgery, and high intensity focused ultrasound.